Showing results (221-230 of 308) with videos related to

Sort By:
Pageof 31
Scientific Reports|April 28, 2022
Airway epithelial interferon response to SARS-CoV-2 is inferior to rhinovirus and heterologous rhinovirus infection suppresses SARS-CoV-2 replicationElizabeth R Vanderwall, Kaitlyn A Barrow, Lucille M Rich, et al.
Nature Immunology|April 3, 2007
Local increase in thymic stromal lymphopoietin induces systemic alterations in B cell developmentAlexander Astrakhan, Miyuki Omori, Thuc Nguyen, et al.
Biorxiv : the Preprint Server for Biology|November 30, 2021
Airway epithelial interferon response to SARS-CoV-2 is inferior to rhinovirus and heterologous rhinovirus infection suppresses SARS-CoV-2 replicationElizabeth R Vanderwall, Kaitlyn A Barrow, Lucille M Rich, et al.
Journal of Asthma and Allergy|September 11, 2023
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATORTanya M Laidlaw, Andrew Menzies-Gow, Scott Caveney, et al.
Journal of Immunology Research|October 30, 2023
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood NeutrophilsEugene R Bleecker, Reynold A Panettieri, Njira L Lugogo, et al.
The Journal of Allergy and Clinical Immunology|September 16, 2021
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension studyPhilippe Gevaert, Rebecca Saenz, Jonathan Corren, et al.
Immunity|May 15, 2012
Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiencyMatthew L Bettini, Fan Pan, Maria Bettini, et al.
Mucosal Immunology|February 28, 2020
Thymic stromal lymphopoietin protects in a model of airway damage and inflammation via regulation of caspase-1 activity and apoptosis inhibitionNicholas J Shubin, Morgan Clauson, Kerri Niino, et al.
The Journal of Allergy and Clinical Immunology|November 7, 2017
Interferon response to respiratory syncytial virus by bronchial epithelium from children with asthma is inversely correlated with pulmonary functionMatthew C Altman, Stephen R Reeves, Andrew R Parker, et al.
Allergy|July 11, 2023
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids doseIan D Pavord, Arnaud Bourdin, Alberto Papi, et al.
Pageof 31